NCT06604520View on ClinicalTrials.gov

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

September 1, 2029

Conditions
Fronto-temporal DementiaFronto-temporal Lobar DementiaFrontotemporal DegenerationFrontotemporal Dementia (FTD)Frontotemporal Dementia, Behavioral VariantFrontotemporal Dementia
Interventions
DRUG

Vortioxetine

Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine

Trial Locations (1)

21287

RECRUITING

The Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Lundbeck LLC
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Lundbeck LLC

INDUSTRY

lead

Johns Hopkins University

OTHER